Waldenström's macroglobulinaemia secreting a paraprotein with lupus anticoagulant activity: possible association with gastrointestinal tract disease and malabsorption.

Tait, Robert C.; Oogarah, P K; Houghton, John; Farrand, S E; Haeney, M R

doi:10.1136/jcp.46.7.678

Cited by 14 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In lymphoplasmacytic lymphoma (LPL), the high prevalence of palpable or sonographic splenomegaly (in all but one of all evaluable cases) is in contrast to a 12-18% splenomegaly reported in larger series [66][67][68]. The association of LA with intestinal obstruction in LPL is noteworthy [30,31].…”

Section: Lupus Anticoagulantsmentioning

confidence: 88%

Acquired immune-mediated thrombophilia in lymphoproliferative disorders

Lechner

Simonitsch

Haselböck³

et al. 2011

Leukemia & Lymphoma

View full text Add to dashboard Cite

We analyzed 66 cases of immune-mediated thrombophilia in patients with lymphoma reported in the literature. Sixty-one cases had a lupus anticoagulant, three an antibody to protein S, one to protein C, and one to ADAMTS 13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13). Lupus anticoagulants occurred in all histological subtypes of non-Hodgkin lymphoma, except mantle cell lymphoma, MALT (mucosa-associated lymphoid tissue) lymphoma, and angioimmunoblastic T-cell lymphoma, and rarely in Hodgkin lymphoma. The largest number of cases was described in splenic marginal zone and lymphoplasmacytic lymphoma. Lupus anticoagulants were highly associated with immunoglobulin M (IgM) paraproteinemia, autoimmune hemolytic anemia, and immune thrombocytopenia. About half of the patients had thrombotic events (antiphospholipid antibody syndrome). Venous thromboembolism was more than twice as common as arterial thrombosis; 6.5% had a catastrophic antiphospholipid antibody syndrome. The lupus anticoagulant could be eliminated by lymphoma treatment (chemoimmunotherapy or splenectomy) in more than one-third of patients. It is suggested that a search for lupus anticoagulant should be done in all patients with lymphoma, because a diagnosis of lupus anticoagulant may influence the management of lymphomas in some patients.

show abstract

Section: Lupus Anticoagulantsmentioning

confidence: 88%

Acquired immune-mediated thrombophilia in lymphoproliferative disorders

Lechner

Simonitsch

Haselböck³

et al. 2011

Leukemia & Lymphoma

View full text Add to dashboard Cite

show abstract

“…The ability of monoclonal paraprotein to function as an autoantibody has been increasingly recognized and it has been linked to a number of systemic clinical presentations. Antiphospholipid (aPL) antibodies have been reported in the presence of monoclonal gammopathies [95][96][97]. These may have no clinical manifestation, or can be linked to thrombotic events.…”

Section: Autoantibody I Antiphospholipid (Apl) Autoantibodiesmentioning

confidence: 99%

Monoclonal Gammopathy of Thrombotic Significance

Gkalea

Fotiou

Dimopoulos

et al. 2023

Cancers

View full text Add to dashboard Cite

The current review provides an overview of the thrombotic risk observed in patients with MG who do not otherwise require treatment. We discuss clinical and biomarker studies that highlight the heterogenous hemostatic profile observed in these patients and how knowledge has evolved over the past 20 years. Biomarker studies suggest shared biologic features between multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS), which involves both hypercoagulability and platelet activation. Hemostatic abnormalities identified in MGUS patients cannot be translated into clinical practice as they lack correlation to clinical events. The prothrombotic phenotype of MGUS patients has not been ascertained yet, but novel data on coagulation markers are promising. We also review rare conditions associated with the thrombogenic properties of the monoclonal protein that predispose to arterial, venous or microthrombotic events and demonstrate that the M-protein can be linked to clinically significant thrombotic events. Cryoglobulinemia, cryofibrinogenemia, cryo-crystaloglobulinemia and MG-related antiphospholipid syndrome are reviewed. We propose the new umbrella term “monoclonal gammopathy of thrombotic significance” (MGTS) to refer to significant, recurrent thrombotic events in patients with MGUS that provide a rationale for targeting the underlying plasma cell clone. Identifying MGUS patients at high risk for thrombotic events is currently a challenge.

show abstract

“…Case reports have described the presence of aPL antibodies in monoclonal gammopathies. [9][10][11][12][13][14] Some have had thrombotic events and others have described aPL activity attributed to the identified paraprotein.…”

mentioning

confidence: 99%

“…These cases have demonstrated either incidental aPL antibodies in patients with monoclonal gammopathy or following thrombotic events, for which aPL antibodies were considered as a contributing or causative factor. [9][10][11][12][13][14] Other aPL-antibody-mediated conditions such as lupus anticoagulant hypoprothrombinemia syndrome presenting with a bleeding diathesis have been described with multiple myeloma. 18,19 Paraproteins with aPL-antibody activity in patients with a variety of monoclonal disorders, including myeloma and Waldenström's macroglobulinemia, have been described.…”

mentioning

confidence: 99%